SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

TESARO, Inc. – IPO: ‘S-1/A’ on 5/16/12 – EX-4.3

On:  Wednesday, 5/16/12, at 6:29pm ET   ·   As of:  5/17/12   ·   Accession #:  1047469-12-6122   ·   File #:  333-180309

Previous ‘S-1’:  ‘S-1’ on 3/23/12   ·   Next:  ‘S-1/A’ on 5/25/12   ·   Latest:  ‘S-1/A’ on 2/25/13

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 5/17/12  TESARO, Inc.                      S-1/A       5/16/12    9:8.8M                                   Merrill Corp/New/FA

Initial Public Offering (IPO):  Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Pre-Effective Amendment to Registration Statement   HTML   1.35M 
                          (General Form)                                         
 2: EX-4.2      Instrument Defining the Rights of Security Holders  HTML    362K 
 3: EX-4.3      Instrument Defining the Rights of Security Holders  HTML    204K 
 4: EX-10.17    Material Contract                                   HTML    467K 
 5: EX-10.18    Material Contract                                   HTML    424K 
 6: EX-10.19    Material Contract                                   HTML    245K 
 7: EX-23.1     Consent of Experts or Counsel                       HTML      8K 
 8: EX-99.1     Miscellaneous Exhibit                               HTML   1.20M 
 9: EX-99.2     Miscellaneous Exhibit                               HTML   1.92M 


EX-4.3   —   Instrument Defining the Rights of Security Holders


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]




Exhibit 4.3

 

EXECUTION COPY

 

AMENDMENT NO. 1

 

TO

 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

The Second Amended and Restated Investors’ Rights Agreement (the “Investors’ Rights Agreement”), dated as of June 6, 2011, by and among TESARO, INC., a Delaware corporation (the “Company”), and the other parties thereto, is hereby amended as of July 7, 2011.

 

WHEREAS, the Company is party to that certain Series B Preferred Stock Purchase Agreement, dated as of June 6, 2011, by and among the Company and the Investors party thereto (as amended, the “Purchase Agreement”);

 

WHEREAS, pursuant to Section 4.7 of the Investors’ Rights Agreement, the Company may amend the Investors’ Rights Agreement only with the written consent of the holders of (i) a majority of the then-outstanding shares of Series A Preferred Stock, (ii) at least sixty percent (60%) of the then-outstanding shares of Series B Preferred Stock, including either InterWest Partners X, LP or KPCB Holdings, Inc., so long as InterWest Partners X, LP and KPCB Holdings, Inc. are Major Investors, and (iii) with respect to Section 3.5 of the Investors’ Rights Agreement, a majority of Registrable Securities that are held by Major Investors (collectively, a “Requisite Majority”); and

 

WHEREAS, in connection with entering into an amendment to the Purchase Agreement and the issuance and sale by the Company of Additional Shares to Additional Purchasers (as such terms are defined in the Purchase Agreement), including to Venrock Healthcare Capital Partners, L.P., the Company and the undersigned parties to the Investors’ Rights Agreement, constituting a Requisite Majority, have agreed to amend the Investors’ Rights Agreement as set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Investors’ Rights Agreement is hereby amended as follows:

 

1.             Definitions.

 

Capitalized terms appearing herein and not otherwise defined herein shall have the meanings ascribed to such terms in the Investors’ Rights Agreement.

 

2.             Amendments.

 

2.1          Section 3.5 of the Investors’ Rights Agreement is hereby amended by adding a new clause (e) immediately following clause (d) and immediately prior to the ultimate paragraph thereof.  The new clause (e) shall read as follows:

 

“(e)         Venrock Healthcare Capital Partners, L.P. (“Venrock”) is a Major Investor, the Company shall invite a representative of Venrock, who initially shall be Anders Hove, to attend all meetings of the Board of Directors in a nonvoting observer

 



 

capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; provided, however, that such representative shall agree to hold in confidence and trust all information provided and; provided, further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Major Investor or its representative is a Competitor of the Company.”

 

2.2          Section 4.7 of the Investors’ Rights Agreement is hereby amended by (i) deleting the word “and” from immediately prior to clause (d) in the text of the proviso to the third sentence thereof and (ii) adding a new clause (e) the text of such proviso, immediately following clause (d) thereof.  The new clause (e) shall read as follows:

 

“and (e) any amendment or waiver of Section 3.5(e) shall require the consent of Venrock (for such time and for so long as Venrock is a Major Investor)”

 

2.3          Schedule A to the Investors’ Rights Agreement is hereby amended by deleting it and replacing it in its entirety with Schedule A hereto.

 

2.4          Schedule C to the Investors’ Rights Agreement is hereby amended by deleting it and replacing it in its entirety with Schedule C hereto.

 

3.             General.

 

Except as modified by this amendment, which shall be effective as of the first date written above, the Investors’ Rights Agreement shall remain in full force and effect, enforceable in accordance with its terms.

 

[signature page follows]

 

2



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

 

TESARO, INC.

 

 

 

 

 

By:

/s/ Leon O. Moulder, Jr.

 

Name:

Leon O. Moulder, Jr.

 

Title:

Chief Executive Officer

 

 

 

 

 

Address:

309 Waverley Oaks Road, Suite 101

 

 

Waltham, MA 02452

 

 

Attn:

Leon O. Moulder, Jr.

 

 

Phone:

339-970-0901

 

 

E-mail:

lmoulder@tesarobio.com

 

 

Fax:

339-469-8966

 

 

 

 

 

With a copy to:

 

 

 

 

Hogan Lovells US LLP

 

 

100 International Drive, Suite 2000

 

 

Baltimore, MD 21202

 

 

Attn:

Asher M. Rubin

 

 

Phone:

410-659-2777

 

 

E-mail:

asher.rubin@hoganlovells.com

 

 

Fax:

410-659-2701

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR AND FOUNDER:

 

 

 

 

 

LEON O. MOULDER, JR.

 

 

 

 

 

/s/ Leon O. Moulder, Jr.

 

 

 

 

 

Address:

18132 Via Caprini Drive

 

 

Miromar Lakes, FL 33913

 

 

Phone:

339-970-0901

 

 

E-mail:

lmoulder@tesarobio.com

 

 

Fax:

339-469-8966

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR AND FOUNDER:

 

 

 

 

 

MARY LYNNE HEDLEY

 

 

 

 

 

/s/ Mary Lynne Hedley

 

 

 

 

 

Address:

51 Follen Road

 

 

Lexington, MA 02421

 

 

Phone:

339-970-0902

 

 

E-mail:

mlhedley@tesarobio.com

 

 

Fax:

339-469-8967

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR AND FOUNDER:

 

 

 

 

 

RICHARD J. RODGERS

 

 

 

 

 

/s/ Richard J. Rodgers

 

 

 

 

 

Address:

101 George Street

 

 

Excelsior, MN 55331

 

 

Phone:

339-970-0903

 

 

E-mail:

rrodgers@tesarobio.com

 

 

Fax:

339-469-8965

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR:

 

 

 

 

 

NEW ENTERPRISE ASSOCIATES 13, LIMITED PARTNERSHIP

 

 

 

By:

NEA Partners 13, Limited Partnership

 

 

its general partner

 

 

 

 

 

By:

NEA GP 13, LTD, its general partner

 

 

 

 

 

 

 

By:

/s/ Louis A. Citron

 

 

 

Name:

Louis A. Citron

 

 

 

Title:

Chief Legal Officer

 

 

 

 

 

NEA VENTURES 2010, LIMITED PARTNERSHIP

 

 

 

 

 

 

By:

/s/ Louis A. Citron

 

Name:

Louis A. Citron

 

Title:

Vice-President

 

 

 

 

 

Address:

5245 Wisconsin Avenue, Suite 800

 

 

Chevy Chase, MD 20815

 

 

Attn:

Louis Citron

 

 

Phone:

410-842-4105

 

 

E-mail:

lcitron@nea.com

 

 

Fax:

301-272-1725

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR:

 

 

 

 

 

SARA NAYEEM, M.D.

 

 

 

 

 

/s/ Sara Nayeem, M.D.

 

 

 

 

 

 

Address:

c/o New Enterprises Associates 13, Limited Partnership

 

 

5245 Wisconsin Avenue, Suite 800

 

 

Chevy Chase, MD 20815

 

 

Attn:

Louis Citron

 

 

Phone:

410-842-4105

 

 

E-mail:

lcitron@nea.com

 

 

Fax:

301-272-1725

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR:

 

 

 

 

 

INTERWEST PARTNERS X, LP

 

By:

InterWest Management Partners X, LLC, its general partner

 

 

 

 

 

 

 

 

By:

/s/ Arnold L. Oronsky

 

 

Name:

Arnold L. Oronsky

 

 

Title:

Managing Director

 

 

 

 

 

Address:

InterWest Partners

 

 

2710 Sand Hill Road, 2nd Floor

 

 

Menlo Park, CA 94025

 

 

Attn:

Karen Wilson

 

 

Phone:

650-854-8585

 

 

E-mail:

kwilson@interwest.com

 

 

Fax:

650-854-4706

 

 

 

 

 

With a copy to:

 

 

 

 

Gunderson Detmer Stough Villeneuve

 

 

Franklin & Hachigian, LLP

 

 

1200 Seaport Blvd.

 

 

Redwood City, CA 94063

 

 

Attn:

Marcia A. Hatch

 

 

Phone:

650-463-5266

 

 

E-mail:

mhatch@gunder.com

 

 

Fax:

877-881-6112

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 


 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR:

 

 

 

 

 

KPCB HOLDINGS, INC.,

 

as nominee

 

 

 

 

 

By:

/s/ Brook Byers

 

Name:

Brook Byers

 

Title:

Senior Vice President

 

 

 

 

 

Address:

Kleiner Perkins Caufield & Byers

 

 

2750 Sand Hill Road

 

 

Menlo Park, CA 94025

 

 

Attn:

Sue Biglieri

 

 

Phone:

650-233-3372

 

 

E-mail:

sbiglieri@kpcb.com

 

 

Fax:

650-233-0323

 

 

 

 

 

With a copy to:

 

 

 

 

Gunderson Detmer Stough Villeneuve

 

 

Franklin & Hachigian, LLP

 

 

1200 Seaport Blvd.

 

 

Redwood City, CA 94063

 

 

Attn:

Marcia A. Hatch

 

 

Phone:

650-463-5266

 

 

E-mail:

mhatch@gunder.com

 

 

Fax:

877-881-6112

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR:

 

 

 

 

 

T. ROWE PRICE ASSOCIATES, INC.

 

Investment Adviser, for and on behalf of the advisory clients on Attachment A to this signature page and listed below:

 

 

 

 

T. Rowe Price Health Sciences Fund, Inc.

 

 

TD Mutual Funds — TD Health Sciences Fund

 

 

Valic Company I — Health Sciences Fund

 

 

T. Rowe Price Health Sciences Portfolio

 

 

John Hancock Trust — Health Sciences Trust

 

 

 

 

 

By:

/s/ Kris H. Jenner

 

Name:

Kris H. Jenner

 

Title:

Vice President

 

 

 

 

 

Address:

T. Rowe Price Associates, Inc.

 

 

100 East Pratt Street

 

 

Baltimore, MD 21202

 

 

Attn:

Andrew Baek, Vice President

 

 

 

and Senior Legal Counsel

 

 

Phone:

410-345-2090

 

 

E-mail:

Andrew_baek@troweprice.com

 

 

Fax:

410-345-6575

 

 

 

With a copy to:

 

 

 

 

Duane Morris LLP

 

 

111 S. Calvert Street, Suite 2000

 

 

Baltimore, MD 21202

 

 

Attn:

Keli Isaacson Whitlock

 

 

Phone:

410-949-2912

 

 

E-mail:

kwhitlock@duanemorris.com

 

 

Fax:

410-949-2952

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR:

 

 

 

 

 

A.M. PAPPAS LIFE SCIENCE VENTURES IV, L.P.

 

By:

AMP&A Management IV, LLC

 

Its:

General Partner

 

 

 

 

 

 

By:

/s/ Ford S. Worthy

 

 

Name:

Ford S. Worthy

 

 

Title:

Partner & CFO

 

 

 

 

 

PV IV CEO FUND, L.P.

 

By:

AMP&A Management IV, LLC

 

Its:

General Partner

 

 

 

 

 

 

By:

/s/ Ford S. Worthy

 

 

Name:

Ford S. Worthy

 

 

Title:

Partner & CFO

 

 

 

 

 

Address:

c/o Pappas Ventures

 

 

P. O. Box 110287

 

 

Research Triangle Park, NC 27709

 

 

Attn:

Ford S. Worthy

 

 

Phone:

919-998-3330

 

 

E-mail:

fworthy@pappasventures.com

 

 

Fax:

919-998-3301

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR:

 

 

 

 

 

LEERINK SWANN HOLDINGS, LLC

 

 

 

 

 

By:

/s/ Timothy A.G. Gerhol

 

Name:

Timothy A.G. Gerhold

 

Title:

General Counsel

 

 

 

 

 

LEERINK SWANN CO-INVESTMENT FUND, LLC

 

 

 

 

 

By:

/s/ Joseph R. Gentile

 

Name:

Joseph R. Gentile

 

Title:

CAO

 

 

 

 

 

Address:

Leerink Swann LLC

 

 

One Federal Street, 37th Floor

 

 

Boston, MA 02110

 

 

Attn:

Timothy Gerhold, Esq.

 

 

Phone:

617-918-4514

 

 

E-mail:

tim.gerhold@leerink.com

 

 

Fax:

617-918-4720

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR:

 

 

 

 

 

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

 

 

 

By:

Deerfield Capital, L.P.

 

 

General Partner

 

 

 

 

By:

J.E. Flynn Capital, LLC

 

 

 

General Partner

 

 

 

 

 

 

 

By:

/s/ David J. Clark

 

 

 

Name:

David J. Clark

 

 

 

Title:

Authorized Signatory

 

 

 

 

 

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL, LIMITED

 

 

 

 

 

By:

/s/ David J. Clark

 

Name:

David J. Clark

 

Title:

Authorized Signatory

 

 

 

 

 

Address:

c/o Deerfield Management Co.

 

 

780 Third Ave., 37th Fl.

 

 

New York, NY 10017

 

 

Attn:

David J. Clark

 

 

Phone:

646-536-5661

 

 

E-mail:

DClark@deerfieldpartners.com

 

 

Fax:

646-536-5662

 

 

 

 

 

With a copy to:

 

 

 

 

Katten Muchin Rosenman LLP

 

 

575 Madison Avenue

 

 

New York, NY 10022-2585

 

 

Attn:

Mark I. Fisher

 

 

Phone:

212-940-8877

 

 

E-mail:

mark.fisher@kattenlaw.com

 

 

Fax:

212-894-5877

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR:

 

 

 

 

 

ORACLE PARTNERS, LP

 

 

 

By:

Oracle Associates, LLC,

 

 

its General Partner

 

 

 

 

 

 

By:

/s/ Larry N. Feinberg

 

 

Name:

Larry N. Feinberg

 

 

Title:

Managing Member

 

 

 

 

 

ORACLE INSTITUTIONAL PARTNERS, LP

 

 

 

By:

Oracle Associates, LLC,

 

 

its General Partner

 

 

 

 

 

 

By:

/s/ Larry N. Feinberg

 

 

Name:

Larry N. Feinberg

 

 

Title:

Managing Member

 

 

 

 

 

Address:

Oracle Investment Management, Inc.

 

 

200 Greenwich Avenue

 

 

Greenwich, CT 06830

 

 

Attn:

Aileen Wiate

 

 

Phone:

203-862-7980

 

 

E-mail:

awiate@oraclepartners.com

 

 

Fax:

203-862-7982

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Second Amended and Restated Investors’ Rights Agreement as of the date first written above.

 

 

INVESTOR:

 

 

 

 

 

OPKO HEALTH, INC.

 

 

 

 

 

By:

/s/ Steven D. Rubin

 

Name:

Steven D. Rubin

 

Title:

Exec. V.P.

 

 

 

 

 

Address:

4400 Biscayne Boulevard

 

 

Miami, FL 33137

 

 

Attn:

Kate Inman

 

 

Phone:

(305) 575-4138

 

 

E-mail:

kinman@opko.com

 

 

Fax:

 

 

SIGNATURE PAGE TO AMENDMENT NO. 1 TO THE SERIES B PREFERRED SECOND AMENDED AND

RESTATED INVESTORS’ RIGHTS AGREEMENT FOR TESARO, INC.

 



 

SCHEDULE A

 

Investors

 

Series A Investor:

 

Shares of Series A Preferred Stock:

 

New Enterprise Associates 13, Limited Partnership

 

17,970,000

 

NEA Ventures 2010, Limited Partnership

 

25,000

 

Sara Nayeem

 

5,000

 

Leon O. Moulder, Jr.

 

1,500,000

 

Mary Lynn Hedley

 

250,000

 

Richard J. Rodgers

 

250,000

 

 

Series B Investor:

 

Shares of Series B Preferred Stock:

 

New Enterprise Associates 13, Limited Partnership

 

7,741,199

 

Sara Nayeem

 

2,298

 

InterWest Partners X, LP

 

3,871,748

 

KPCB Holdings, Inc.

 

2,903,811

 

T. Rowe Price Health Sciences Fund, Inc.

 

972,450

 

TD Mutual Funds — TD Health Sciences Fund

 

49,821

 

VALIC Company I — Health Sciences Fund

 

68,928

 

T. Rowe Price Health Sciences Portfolio

 

18,322

 

John Hancock Trust — Health Sciences Trust

 

51,999

 

A.M. Pappas Life Science Ventures IV, L.P.

 

923,959

 

PV IV CEO FUND, L.P.

 

43,977

 

Leerink Swann Holdings, LLC

 

193,587

 

Leerink Swann Co-Investment Fund, LLC

 

193,587

 

Deerfield Special Situations Fund, L.P.

 

150,998

 

Deerfield Special Situations Fund International, Limited

 

236,176

 

Oracle Partners, LP

 

792,251

 

Oracle Institutional Partners, LP

 

175,685

 

Venrock Healthcare Capital Partners, L.P.

 

818,256

 

VHCP Co-Investment Holdings, LLC

 

149,680

 

Frost Gamma Investments Trust

 

193,587

 

 



 

SCHEDULE C

 

Major Investors

 

New Enterprise Associates 13, Limited Partnership

 

InterWest Partners X, LP

 

KPCB Holdings, Inc.

 

T. Rowe Price Associates, Inc. (Investment Adviser, for and on behalf of the following advisory clients and their nominees: T. Rowe Price Health Sciences Fund, Inc., TD Mutual Funds — TD Health Sciences Fund, VALIC Company I — Health Sciences Fund, T. Rowe Price Health Sciences Portfolio, John Hancock Trust — Health Sciences Trust)

 

A.M. Pappas Life Science Ventures IV, L.P.

 

Venrock Healthcare Capital Partners, L.P.

 




Dates Referenced Herein

This ‘S-1/A’ Filing    Date    Other Filings
Filed as of:5/17/12None on these Dates
Filed on:5/16/12
7/7/11
6/6/11
 List all Filings 
Top
Filing Submission 0001047469-12-006122   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 6:02:19.1am ET